Shizuyo Tsujimura Yoshiya Tanaka
10.2169/internalmedicine.2589-18
Intern Med
2019;58(21):3173-3178.
cd4+ cell methotrexate p-glycoprotein diffuse proliferative lupus nephritis
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/31685786/
CD4-Positive T-Lymphocytes / drug effects Cyclophosphamide / administration & dosage Immunosuppressive Agents / administration & dosage Lupus Nephritis / drug therapy Methotrexate / administration & dosage
CD4-Positive T-Lymphocytes / drug effects Cyclophosphamide / administration & dosage Immunosuppressive Agents / administration & dosage Lupus Nephritis / drug therapy Methotrexate / administration & dosage Case Reports ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism Administration, Intravenous Adult Drug Administration Schedule Drug Resistance Drug Therapy, Combination Female Humans Infusions, Intravenous ATP Binding Cassette Transporter, Subfamily B, Member 1 Immunosuppressive Agents Cyclophosphamide Methotrexate
PMC6875445
31685786
Treatment with Methotrexate and Intravenous Cyclophosphamide Pulse Therapy Regulates the P-gp+CD4+ Cell-related Pathogenesis in a Representative Patient with Refractory Proliferative Lupus Nephritis
2019